Trials / Active Not Recruiting
Active Not RecruitingNCT05683691
Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer
Prospective, Multicenter, Single-Arm Study of VanquishTM Water Vapor Ablation for PrOstate CanceR
- Status
- Active Not Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 400 (estimated)
- Sponsor
- Francis Medical Inc. · Industry
- Sex
- Male
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of the Vanquish Water Vapor Ablation Device ("Vanquish") in treating subjects with Gleason Grade Group 2 (GGG2) localized intermediate-risk prostate cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Vanquish System | Water vapor ablation delivered transurethrally in patients with intermediate risk, localized prostate cancer. |
Timeline
- Start date
- 2023-05-16
- Primary completion
- 2027-04-01
- Completion
- 2029-04-01
- First posted
- 2023-01-13
- Last updated
- 2026-04-13
Locations
25 sites across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT05683691. Inclusion in this directory is not an endorsement.